Literature DB >> 32063053

Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis.

Ahmad Masri1, Syed Bukhari1, Shahzad Ahmad1, Ricardo Nieves1, Yvonne S Eisele2, William Follansbee1, Amy Brownell1, Timothy C Wong1, Erik Schelbert1, Prem Soman1.   

Abstract

BACKGROUND: Technetium-99 m pyrophosphate protocols for transthyretin cardiac amyloidosis diagnosis have variably used 1- and 3-hour imaging time points. We investigated whether imaging at 1 hour with superior efficiency had comparable diagnostic accuracy as 3-hour imaging.
METHODS: This is a registry analysis of patients with suspected transthyretin cardiac amyloidosis referred for technetium-99 m pyrophosphate at a single tertiary center from June 2015 through January 2019. Patients underwent planar and single-photon emission computed tomography (SPECT) imaging at 1 and 3 hours. A positive Tc-99m pyrophosphate study was defined by the presence of diffuse myocardial tracer uptake on SPECT. For planar imaging, visual semiquantitative (grades 0-3, ≥2 considered positive) and quantitative heart to contralateral ratios (≥1.5 considered positive) were used.
RESULTS: Two hundred thirty-three patients (69% men; median age, 77 [69-83] years) underwent the study protocol. There were 60 (25.8%) patients with diffuse myocardial uptake, 1 (0.4%) with regional uptake, and 172 (73.8%) with no myocardial uptake. Results of SPECT were identical at 1 and 3 hours. Planar imaging at 1 hour had 98% sensitivity and 96% specificity. Planar grade 0 uptake or heart to contralateral ratio ≤1.2 and planar grade 3 uptake or heart to contralateral ratio ≥2.0 were always associated with negative and positive SPECT, respectively. For planar grades 1 and 2 uptake and heart to contralateral ratio 1.3 to 1.9, SPECT was needed to make a diagnosis. No patient with light-chain cardiac amyloidosis had positive SPECT.
CONCLUSIONS: An efficient 1-hour technetium-99 m pyrophosphate protocol had comparable diagnostic performance to a 3-hour protocol.

Entities:  

Keywords:  heart; humans; prealbumin; records; registries

Mesh:

Substances:

Year:  2020        PMID: 32063053      PMCID: PMC7032611          DOI: 10.1161/CIRCIMAGING.119.010249

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  17 in total

1.  Recognizing Transthyretin Cardiac Amyloidosis in Patients With Aortic Stenosis: Impact on Prognosis.

Authors:  Brett W Sperry; Brandon M Jones; Michael N Vranian; Mazen Hanna; Wael A Jaber
Journal:  JACC Cardiovasc Imaging       Date:  2016-04-13

2.  National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy.

Authors:  Serge C Harb; Muhammad Haq; Kathleen Flood; Angela Guerrieri; Wendy Passerell; Wael A Jaber; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2016-03-25       Impact factor: 5.952

Review 3.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

Review 4.  Prevalence of monoclonal gammopathy of undetermined significance: a systematic review.

Authors:  Rishi K Wadhera; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2010-08-16       Impact factor: 7.616

5.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

6.  (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

Authors:  Sabahat Bokhari; Adam Castaño; Ted Pozniakoff; Susan Deslisle; Farhana Latif; Mathew S Maurer
Journal:  Circ Cardiovasc Imaging       Date:  2013-02-11       Impact factor: 7.792

7.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

Authors:  Adam Castaño; David L Narotsky; Nadira Hamid; Omar K Khalique; Rachelle Morgenstern; Albert DeLuca; Jonah Rubin; Codruta Chiuzan; Tamim Nazif; Torsten Vahl; Isaac George; Susheel Kodali; Martin B Leon; Rebecca Hahn; Sabahat Bokhari; Mathew S Maurer
Journal:  Eur Heart J       Date:  2017-10-07       Impact factor: 29.983

8.  Occult Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis in Patients Undergoing Surgical Aortic Valve Replacement.

Authors:  Thomas A Treibel; Marianna Fontana; Janet A Gilbertson; Silvia Castelletti; Steven K White; Paul R Scully; Neil Roberts; David F Hutt; Dorota M Rowczenio; Carol J Whelan; Michael A Ashworth; Julian D Gillmore; Philip N Hawkins; James C Moon
Journal:  Circ Cardiovasc Imaging       Date:  2016-08       Impact factor: 7.792

9.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins
Journal:  Circulation       Date:  2016-04-22       Impact factor: 29.690

10.  (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.

Authors:  Björn Pilebro; Ole B Suhr; Ulf Näslund; Per Westermark; Per Lindqvist; Torbjörn Sundström
Journal:  Ups J Med Sci       Date:  2016-02-05       Impact factor: 2.384

View more
  15 in total

1.  Variability in bone-seeking tracers and imaging protocols for the diagnosis of cardiac amyloidosis: The more the merrier?

Authors:  Michal Weiler-Sagie; Simona Ben-Haim
Journal:  J Nucl Cardiol       Date:  2020-09-07       Impact factor: 5.952

2.  Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis.

Authors:  Juan Carlo Avalon; Jacob Fuqua; Seth Deskins; Tyler Miller; Justin Conte; Daniel Martin; Gary Marano; Naveena Yanamala; James Mills; Christopher Bianco; Brijesh Patel; Karthik Seetharam; Raymond Raylman; Partho P Sengupta; Yasmin S Hamirani
Journal:  J Nucl Cardiol       Date:  2022-06-02       Impact factor: 5.952

3.  Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.

Authors:  Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu
Journal:  J Nucl Cardiol       Date:  2022-07-21       Impact factor: 3.872

4.  Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis.

Authors:  Golnaz Roshankar; Geneva C White; Sebastien Cadet; Nowell M Fine; Denise Chan; James A White; Victor Jimenez-Zepeda; Piotr J Slomka; Robert J H Miller
Journal:  J Nucl Cardiol       Date:  2021-10-03       Impact factor: 3.872

5.  Optimal interpretation of Tc99m PYP in 2020: Avoiding the million-dollar mistake.

Authors:  Jaime Gerber; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2021-01-13       Impact factor: 5.952

Review 6.  Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2021-07-01       Impact factor: 5.952

7.  Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis.

Authors:  Robert J H Miller; Sebastien Cadet; Darren Mah; Payam Pournazari; Denise Chan; Nowell M Fine; Daniel S Berman; Piotr J Slomka
Journal:  J Nucl Cardiol       Date:  2021-03-10       Impact factor: 5.952

Review 8.  Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021.

Authors:  Weijia Li; Dipan Uppal; Yu-Chiang Wang; Xiaobo Xu; Damianos G Kokkinidis; Mark I Travin; James M Tauras
Journal:  Diagnostics (Basel)       Date:  2021-05-30

9.  Diagnosing Transthyretin Cardiac Amyloidosis by Technetium Tc 99m Pyrophosphate: A Test in Evolution.

Authors:  Timothy J Poterucha; Pierre Elias; Sabahat Bokhari; Andrew J Einstein; Albert DeLuca; Mona Kinkhabwala; Lynne L Johnson; Kathleen R Flaherty; Sunil E Saith; Jan M Griffin; Adler Perotte; Mathew S Maurer
Journal:  JACC Cardiovasc Imaging       Date:  2020-11-18

Review 10.  Molecular Imaging of Cardiac Amyloidosis.

Authors:  Ahmad Masri; Syed Bukhari; Yvonne S Eisele; Prem Soman
Journal:  J Nucl Med       Date:  2020-06-01       Impact factor: 11.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.